Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

NCT05309213 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia

Interventions

BIOLOGICAL: IM19 CAR-T cells

Sponsor

Beijing Immunochina Medical Science & Technology Co., Ltd.